Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma : A joint study of the french society of pediatric oncology and the United Kingdom Children's cancer study groupVASSAL, Gilles; COUANET, Dominique; CISAR, Laura et al.Journal of clinical oncology. 2007, Vol 25, Num 4, pp 356-361, issn 0732-183X, 6 p.Article

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 TrialROTH, Arnaud D; TEJPAR, Sabine; ARANDA, Enrique et al.Journal of clinical oncology. 2010, Vol 28, Num 3, pp 466-474, issn 0732-183X, 9 p.Article

Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon CancerROTH, Arnaud D; DELORENZI, Mauro; NORDLINGER, Bernard et al.Journal of the National Cancer Institute. 2012, Vol 104, Num 21, pp 1635-1646, issn 0027-8874, 12 p.Article

Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3VAN CUTSEM, Eric; LABIANCA, Roberto; MINI, Enrico et al.Journal of clinical oncology. 2009, Vol 27, Num 19, pp 3117-3125, issn 0732-183X, 9 p.Article

Phase I clinical and pharmacologic trial of intravenous estramustine phosphateHUDES, Gary; HAAS, Naomi; KOPRESKI, Michael et al.Journal of clinical oncology. 2002, Vol 20, Num 4, pp 1115-1127, issn 0732-183XArticle

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane StudyBLISS, Judith M; KILBURN, Lucy S; DE VELDE, Cornelis J. H. Van et al.Journal of clinical oncology. 2012, Vol 30, Num 7, pp 709-717, issn 0732-183X, 9 p.Article

A phase II study of irinotecan in children with relapsed or refractory neuroblastoma : A European cooperation of the Société Francaise d'Oncologie Pediatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG)VASSAL, Gilles; GIAMMARILE, Francesco; PICHON, Fabienne et al.European journal of cancer (1990). 2008, Vol 44, Num 16, pp 2453-2460, issn 0959-8049, 8 p.Article

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rateROCHA LIMA, Caio M; GREEN, Mark R; ROTCHE, Robert et al.Journal of clinical oncology. 2004, Vol 22, Num 18, pp 3776-3783, issn 0732-183X, 8 p.Article

Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunctionSCHAAF, Larry J; HAMMOND, Lisa A; GRUIA, Gabriela et al.Clinical cancer research. 2006, Vol 12, Num 12, pp 3782-3791, issn 1078-0432, 10 p.Article